Lepodisiran

N/A

Report date: 2025/12/08 10:56:17
NME

Base Information

Drug NameLepodisiran
Drug Alias NameLY-3819469DCR-CM2
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApolipoprotein(a) inhibitors
TargetsApolipoprotein(a)
Therapy Area/IndicationsLiver DysfunctionLipid Metabolism DisordersAtherosclerosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDicerna Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyDicerna Pharmaceuticals IncLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver DysfunctionLipid Metabolism DisordersAtherosclerosis +[5] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A